Media Releases

Unedited statements from the health sector and beyond

NZMJ article comparing medicines access - Medicines New Zealand responds

Medicines New ZealandFriday 25 November 2011, 3:09PM

Debate about the optimal level of medicines access for New Zealand patients has received a substantial contribution from internationally respected health economic analysts.

New Zealand patients have been receiving access to new medicines at about half the rate of access provided in Australia, according to an article by Michael Wonder and Richard Milne, published today in the New Zealand Medical Journal (NZMJ). 

The article identifies that some of the products not listed in New Zealand do not have alternatives available locally, and clearly identifies the bottleneck as being within the current PHARMAC system. 

"We recognise that the current Government has shown a commitment to improving the levels of access that PHARMAC can provide by increasing the medicines budget. This has been an important and welcome step towards redressing the situation," Medicines New Zealand General Manager Kevin Sheehy says.

"As the Wonder & Milne report shows however, there is further improvement needed before New Zealand has optimal access. Right now the truth is that access to innovative medicines for New Zealanders is lower and slower than that in Australia.

"The response by PHARMAC staff (also published in the NZMJ) rightly points out a number of the challenges of making international comparisons of access, but does not address the underlying problem of how to improve people's health by offering optimal access to new medicines." Mr Sheehy adds.

The PHARMAC response expresses concern that a few of the medicines are priced at $100 000 per QALY (a measure of their effectiveness in improving health) but does not address the facts that: most of the medicines on offer cost substantially less than this; or that other investments in the health system are being made at this cost with no questions asked.

With PHARMAC moving further into funding hospital medicines, it is vital that the budgeting process is able to respond to increased need for investment. 

A recent consultation about specialist clinicians' views of PHARMAC funding hospital medicines identified the need for a more responsive approach to investing in new medicines. The report states: "A view expressed consistently throughout the consultation period was that PHARMAC's decision-making processes are insufficiently transparent, are too slow and do not adequately involve clinicians." 

ENDS

 
 








Most Popular News

 
Professional Classifieds

Vautier PharmacyNew Pharmacy opening before Christmas. Positions available

Waters&PaulingYour Complete Pharmacy Advisor

DAVID LEWIS PRODUCTS - controlled drug registersControlled drug registers

McCRIMMON LAWEmployment – Commercial & Business – Property

 

Comment Stream

Follow the flow of comment from around the site

Scroll to view recent comments

previous next
That all sounds great. Welcome on board Jonathon. I am hoping you know that pharmacists are wanting...SHOW ME THE MONEY on Pharmacists have primary care role, Coleman says
I see on the CentralTAS website, that the last meeting notes of the CPSGG from 3rd Sept mentions abo...Chris Leggett on CPSA to be extended for 12 months
it is so true Hank. Im NOT being mean to Auckland pharmacy graduates @ all with my following comment...sam on Actavis' refusal to reimburse pharmacists for recall disappointing
I have to agree with Sam. Pharmacy owners have only themselves to blame for non-compensation. This i...Hank on Actavis' refusal to reimburse pharmacists for recall disappointing
MORE COMMENTS